In the present work we have investigated on the mechanism through which stimulation of hERG1 channel leads to a rapid down-regulation of cyclin E2, assessed the impact of this inhibition in tumor cells arising from a variety of breast cancer subtypes, and considered the potential of hERG1 activators in treating breast cancers that have become resistant to therapy. The gene discussed is CCNE2; the disease is breast carcinoma.